The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal ...

Corcept sought FDA approval despite finding relacorilant was statistically no better than placebo in one of two Phase III ...

On December 16, UBS analyst Ashwani Verma initiated coverage of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock with a Neutral rating and $95 price target. In an investor note, the analyst cited ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) is among the best stocks you’ll wish you bought sooner. As of the close of December 2, the consensus shows that analyst opinions are highly favourable ...

Corcept Therapeutics Inc. (NASDAQ:CORT) has reached an unprecedented milestone as its stock price soared to an all-time high of $70.78. This remarkable peak reflects a significant surge in investor ...

Analysts are intrested in these 5 stocks: ( ($DBRG) ), ( ($TKO) ), ( ($GFS) ), ( ($CORT) ) and ( ($AAPL) ). Here is a breakdown of their recent ...

It took longer than expected, but Houston Texans owner Cal McNair finally got his five-high from quarterback C.J. Stroud. McNair and Stroud quickly went viral following the Texans' win over the Kansas ...

Pressure on the Justice Department grew louder Monday after Senate Minority Leader Chuck Schumer, D-N.Y., said he would be introducing a resolution directing the Senate to “initiate legal action ...

Thank you to everyone who entered our 11th Annual Holiday Tech Giveaway! The response this year has been incredible, and we’re grateful for your continued support of Android Headlines. Winner ...